<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577249</url>
  </required_header>
  <id_info>
    <org_study_id>0064476</org_study_id>
    <secondary_id>2CEI-753</secondary_id>
    <nct_id>NCT03577249</nct_id>
  </id_info>
  <brief_title>Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation</brief_title>
  <official_title>Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Città della Salute e della Scienza di Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Città della Salute e della Scienza di Torino</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study 45 patients undergoing weekly dialysis for chronic end stage renal disease will
      be enrolled. The patients will be treated with a standard dialysis solution, containing
      acetate buffer, for 3 months; subsequently the acetate will be substituted with citrate anion
      for the 3 following months and then, the last 3 months, the standard acetate-solution will be
      restarted. The aim of the study is to assess if acetate-to-citrate switch in the dialysis
      solution influences dialysis efficiency and patient inflammatory state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2014</start_date>
  <completion_date type="Actual">July 30, 2015</completion_date>
  <primary_completion_date type="Actual">July 30, 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>45 patients with end stage renal disease will be treated with dialysis solution A (standard of care: acetate-buffered) for 3 months then with solution B (acetate-free, citrate buffered, otherwise identical to solution A) for 3 months and then with solution A for the final 3 months</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum CRP (C-reactive protein)</measure>
    <time_frame>Months 4th to 6th</time_frame>
    <description>Change in serum CRP during the 3 months of citrate-buffered dialysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in dialysis efficiency</measure>
    <time_frame>Every 3 months (month 0, 6, 3 and completion - 9)</time_frame>
    <description>Dougirdas formula will be used to estimate dialysis efficiency at the beginning and completion of each study interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum CRP (C-reactive protein)</measure>
    <time_frame>Every 3 months (month 0, 6, 3 and completion - 9)</time_frame>
    <description>Variation of serum CRP at the beginning and completion of each study interval</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dialysis Solutions</intervention_name>
    <description>Solution A: 3mmol/L of acetate anion; Solution B: 1mmol/L of citrate anion</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18 years

          -  creatinine clearance &lt;5ml/min

          -  treatment with bicarbonate HD (BIC-HD) or on-line hemodiafiltration (OL-HDF) 3 times
             per week for at least 6 months prior to study start

          -  treated at Dialysis unit of: Città della Salute e della Scienza University Hospital,
             Torino, Italy

        Exclusion Criteria:

          -  known neoplastic disease

          -  active chronic inflammatory disease

          -  active acute inflammatory disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Città della Salute e Della Scienza di Torino - Presidi CTO e Molinette</name>
      <address>
        <city>Torino</city>
        <state>To</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Città della Salute e della Scienza di Torino</investigator_affiliation>
    <investigator_full_name>Vincenzo Cantaluppi</investigator_full_name>
    <investigator_title>Associate professor of Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

